Thermo Fisher Scientific shares have been mostly flat during this rally. But the balance sheet is solid, and there is plenty of room for investors to rediscover the stock.

At the cutting edge of laboratory research.

Great growth story in scientific testing

From a recent Mad Money show: "This one's under pressure, but it's the kind of company that should come roaring back. I think it'll do well."

From a recent Mad Money show: "This company is recession resistant, but the market needs to come down before we can buy. This one is a don't-buy for now."

consistant

good to have a scientific/medical stock

To start, the company just got FDA approval for a test that detects the deadly staph superbug – an illness that is reaching epidemic proportions in parts of the U.S. And it doesn’t end there. Thermo Fisher and the broader lab equipment sector are tapped into a sea chance of sorts as 78 million baby boomers anticipate more doctor visits as they grow older. That’s why the fastest money on the Street has put TMO under the microscope – and they like what they see.

3 Stocks I Saw on TV
Dan Fitzpatrick examines three stocks viewed on 'Fast Money' -- Microsoft, Thermo Fisher and Merrill Lynch.

Click here to watch the video.

scientific

not much success for so much hype